-
Novaflux Technologies
Distance: 3.3 Mi1 Wall St
8540 Princeton -
Bioinsights, Inc.
Distance: 7.1 Mi153 Dorchester Dr
08520 Hightstown -
Juvent
Distance: 12.5 Mi300 Atrium Dr 2nd Fl
08873 Somerset -
Key Recruit, Inc.
Distance: 13.0 MiPO Box 1531
8043 Voorhees -
Larchmont Imaging Associates, L.L.C
Distance: 26.8 Mi1295 Route 38
08036-2702 Hainesport
Description
MedNest at Work: Selected Clients List Our client are international and innovative medical technology companies in different development stages. These companies are looking for an experienced partner to operate their organic or inorganic growth projects, in particular during transition times (i.e. US Market Access preparation, deal search or post-acquisition integration), when execution risks and time to market must be minimal. Our clients' technologies fit in the Drug- Device & Diagnostics - Healthcare IT convergence space and are headquartered around the globe, in New Zealand, Singapore, France, Luxembourg, USA, Switzerland, Scotland etc... Please find below a selection of our clients. Do not hesitate to contact us if you want to know more about these companies and their growth plans. Venture Overview: For cervical, thoracic or lumbar spine surgery, S14Implants designs implants to treat degenerative spinal pathologies as well as deformities of the vertebral column, invents new concepts of dynamic stabilization overcoming the inter vertebral disc insufficiencies and invents growing implantable devices to correct without fusion the scoliosis of the young children. Some entry-level S14's products have obtained CE mark, and other advanced implants have been used in research for the past 3 years, with very positive outcomes. MedNest Contribution: As a precursor activity to S14 US market entry, MedNest as studied the clinical relevance of S14's implants for the US healthcare system and secured several prestigious institutions for clinical trials. 7 Key Opinion Leaders have been engaged in very productive clinical, regulatory and business discussions that validated the potential of S14's implants in the US, but also enriched S14's clinical and regulatory strategy to enter the US. Next steps will be to trigger the regulatory plans (PME) and Clinical Plans (Protocol, IRB, deployment and implementation) to secure a successful evaluation, 510k approval and clinical adoption.